137 related articles for article (PubMed ID: 8071685)
21. Pregnancy outcome after treatment with radioiodine for differentiated thyroid carcinoma.
Balenović A; Vlasić M; Sonicki Z; Bodor D; Kusić Z
Coll Antropol; 2006 Dec; 30(4):743-8. PubMed ID: 17243543
[TBL] [Abstract][Full Text] [Related]
22. Radioiodine therapy for papillary and follicular thyroid carcinoma.
Klain M; Ricard M; Leboulleux S; Baudin E; Schlumberger M
Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S479-85. PubMed ID: 12192549
[TBL] [Abstract][Full Text] [Related]
23. Testicular function after radioiodine therapy in patients with thyroid cancer.
Rosário PW; Barroso AL; Rezende LL; Padrão EL; Borges MA; Guimarães VC; Purisch S
Thyroid; 2006 Jul; 16(7):667-70. PubMed ID: 16889490
[TBL] [Abstract][Full Text] [Related]
24. Pregnancy outcome after diagnosis of differentiated thyroid carcinoma: no deleterious effect after radioactive iodine treatment.
Chow SM; Yau S; Lee SH; Leung WM; Law SC
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):992-1000. PubMed ID: 15234032
[TBL] [Abstract][Full Text] [Related]
25. Effects of radioiodine treatment for differentiated thyroid cancer on testis function.
Canale D; Ceccarelli C; Caglieresi C; Moscatelli A; Gavioli S; Santini P; Elisei R; Vitti P
Clin Endocrinol (Oxf); 2015 Feb; 82(2):295-9. PubMed ID: 25138547
[TBL] [Abstract][Full Text] [Related]
26. Testicular function after radioiodine therapy for thyroid carcinoma.
Wichers M; Benz E; Palmedo H; Biersack HJ; Grünwald F; Klingmüller D
Eur J Nucl Med; 2000 May; 27(5):503-7. PubMed ID: 10853804
[TBL] [Abstract][Full Text] [Related]
27. Preparation with recombinant human thyroid-stimulating hormone for thyroid remnant ablation with 131I is associated with lowered radiotoxicity.
Rosário PW; Borges MA; Purisch S
J Nucl Med; 2008 Nov; 49(11):1776-82. PubMed ID: 18927337
[TBL] [Abstract][Full Text] [Related]
28. Prognostic factors in well-differentiated thyroid carcinoma in patients treated and followed in the same institution.
Cappelli C; Pirola I; Braga M; De Martino E; Morassi ML; Gandossi E; Mattanza C; Balzano R; Castellano M; Rosei EA
Ann Ital Chir; 2006; 77(2):107-13. PubMed ID: 17147082
[TBL] [Abstract][Full Text] [Related]
29. Testicular dose and fertility in men following I(131) therapy for thyroid cancer.
Hyer S; Vini L; O'Connell M; Pratt B; Harmer C
Clin Endocrinol (Oxf); 2002 Jun; 56(6):755-8. PubMed ID: 12072044
[TBL] [Abstract][Full Text] [Related]
30. Impact on testicular function of a single ablative activity of 3.7 GBq radioactive iodine for differentiated thyroid carcinoma.
Bourcigaux N; Rubino C; Berthaud I; Toubert ME; Donadille B; Leenhardt L; Petrot-Keller I; Brailly-Tabard S; Fromigué J; de Vathaire F; Simon T; Siffroi JP; Schlumberger M; Bouchard P; Christin-Maitre S
Hum Reprod; 2018 Aug; 33(8):1408-1416. PubMed ID: 29912343
[TBL] [Abstract][Full Text] [Related]
31. Should we routinely offer a second admission for radioiodine to patients with high-risk differentiated thyroid cancer?
Gerrard GE; O'Toole L; Roberts F
Clin Oncol (R Coll Radiol); 2010 Mar; 22(2):136-9. PubMed ID: 20152708
[TBL] [Abstract][Full Text] [Related]
32. Radiation dose to the testes after 131I therapy for ablation of postsurgical thyroid remnants in patients with differentiated thyroid cancer.
Ceccarelli C; Battisti P; Gasperi M; Fantuzzi E; Pacini F; Gualdrini G; Pierantoni MC; Luciani A; Djokich D; Pinchera A
J Nucl Med; 1999 Oct; 40(10):1716-21. PubMed ID: 10520714
[TBL] [Abstract][Full Text] [Related]
33. Thallium-201 scintigraphy to predict therapeutic outcome of iodine-131 therapy of metastatic thyroid carcinoma.
Nakada K; Katoh C; Kanegae K; Tsukamoto E; Shiga T; Mochizuki T; Itoh K; Tamaki N
J Nucl Med; 1998 May; 39(5):807-10. PubMed ID: 9591580
[TBL] [Abstract][Full Text] [Related]
34. Subsequent fertility and birth histories of children and adolescents treated with 131I for thyroid cancer.
Sarkar SD; Beierwaltes WH; Gill SP; Cowley BJ
J Nucl Med; 1976 Jun; 17(6):460-4. PubMed ID: 944243
[TBL] [Abstract][Full Text] [Related]
35. Testicular damage after radioactive iodine (I-131) therapy for thyroid cancer.
Handelsman DJ; Turtle JR
Clin Endocrinol (Oxf); 1983 May; 18(5):465-72. PubMed ID: 6409459
[TBL] [Abstract][Full Text] [Related]
36. One size does not fit all: the merit of absorbed doses to the blood in 131I therapy for differentiated thyroid carcinoma.
Fatholahi L; Tabeie F; Pashazadeh AM; Javadi H; Assadi M; Asli IN
Health Phys; 2015 Jan; 108(1):53-8. PubMed ID: 25437520
[TBL] [Abstract][Full Text] [Related]
37. [Effects of 131I therapy on peripheral blood in children and adolescents with differentiated thyroid carcinoma].
Wang J; Zhao W; Liu B; Kuang A
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2011 Dec; 28(6):1185-8. PubMed ID: 22295711
[TBL] [Abstract][Full Text] [Related]
38. Assessment of female fertility and carcinogenesis after iodine-131 therapy for differentiated thyroid carcinoma.
Dottorini ME; Lomuscio G; Mazzucchelli L; Vignati A; Colombo L
J Nucl Med; 1995 Jan; 36(1):21-7. PubMed ID: 7799075
[TBL] [Abstract][Full Text] [Related]
39. Oxidative stress in patients with differentiated thyroid cancer: early effects of radioiodine therapy.
Vrndic OB; Radivojevic SD; Jovanovic MD; Djukic SM; Teodorovic LC; Simonovic ST
Indian J Biochem Biophys; 2014 Jun; 51(3):223-9. PubMed ID: 25204085
[TBL] [Abstract][Full Text] [Related]
40. Radioprotection of salivary glands by amifostine in high-dose radioiodine treatment. Results of a double-blinded, placebo-controlled study in patients with differentiated thyroid cancer.
Bohuslavizki KH; Klutmann S; Brenner W; Kröger S; Buchert R; Bleckmann C; Mester J; Henze E; Clausen M
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():6-12. PubMed ID: 10584133
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
